Event‐free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group
Jonathan Metts,
Wei Xue,
Zhengya Gao
et al.
Abstract:BackgroundNovel therapies are needed for relapsed and refractory rhabdomyosarcoma (RRMS). Phase II clinical trials in RRMS have typically utilized radiologic response as the primary activity endpoint, an approach that poses several limitations in RRMS. In this analysis, we aimed to estimate an event‐free survival (EFS) endpoint for RRMS that could be used as a benchmark for future studies.ProcedureWe performed a retrospective study of patients with RRMS enrolling on 13 single‐agent phase II Children's Oncology… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.